Apply to KAUST
Moving to KAUST
Search for Jobs
KAUST is joining universities around the world to make licensing opportunities rapidly available and get technologies that prevent, diagnose, treat and contain COVID-19 to market.
In response to the virus, KAUST researchers have shifted their capabilities to develop solutions to the COVID-19 pandemic in collaboration with the Kingdom of Saudi Arabia's healthcare stakeholders, including the Saudi Centers for Disease Control and Ministry of Health. KAUST research efforts are focusing on the development of rapid diagnostic platforms, genomic analyses and tools to help track the spread and evolution of the virus.
"KAUST is in a unique position in Saudi Arabia and the Middle East to significantly contribute to the development of new technologies that can help mitigate the COVID-19 pandemic. IP licensing typically takes months to finalize with significant financial and legal costs to both parties. By making KAUST technology easily accessible, we can speed up the development of technologies and make them public more quickly," explained Sean Flanigan, Director of Technology Transfer at KAUST.
KAUST has become a signatory to both the AUTM COVID-19 Licensing Guidelines and adopted the COVID-19 Technology Development Framework, initiated by Massachusetts Institute of Technology, Stanford and Harvard.
Both frameworks ensure that KAUST intellectual property will allow for royalty-free, time-limited, non-exclusive licenses during the pandemic and for a period after it ends. The program takes advantage of our express licensing documentation developed under the KAUST Easy Access Program (KEAP) introduced in 2019 to accelerate the translation of research out of the University.
The University's commitments are formally defined by the statement that follows:
We strongly believe that while intellectual property rights can often serve to incentivize the creation of new products, such rights should not become a barrier to addressing widespread, urgent and essential health-related needs. To address the global COVID-19 pandemic, we are each implementing technology transfer strategies to allow for and incentivize rapid utilization of our available technologies that may be useful for preventing, diagnosing and treating COVID-19 infection during the pandemic.
To achieve our common goal, we each individually commit to the following guidelines:
Read the full text of the COVID-19 Technology Development Framework.
For more information about licensing a KAUST technology, contact TTO@kaust.edu.sa